Alzheimer's Disease

Consuming unsweetened caffeinated coffee is linked to a lower risk of Alzheimer’s, Parkinson’s, and related mortality, while sweetened or artificially sweetened coffee showed no such benefits.

A small study found that focused ultrasound safely reduced amyloid plaques and improved neuropsychiatric symptoms in Alzheimer’s patients without medication, offering a promising new treatment approach by targeting the brain’s blood-brain barrier.

Researchers found that the immune enzyme TYK2 adds a tag to tau protein, causing toxic buildup in the brain. Blocking TYK2 reduced harmful tau and neuron damage in mice, offering a potential new target for Alzheimer’s treatment.

Alzheimer’s disease and alcohol use disorder share similar gene expression changes, including increased inflammation, disrupted brain signaling, and vascular damage, suggesting alcohol use may worsen or accelerate Alzheimer’s progression through shared molecular mechanisms.

Bilingual individuals with Alzheimer’s disease showed preserved hippocampal volume compared to monolinguals, suggesting bilingualism may provide brain maintenance benefits.

A high dose of nicotinamide, tested as a treatment for early-stage Alzheimer’s, showed no significant impact on reducing harmful tau proteins in the brain.

A rare genetic variant, APOE3 Christchurch, delays Alzheimer's onset by years in high-risk individuals, offering insights into disease resilience. This discovery could guide new treatments targeting similar protective pathways for Alzheimer’s prevention and therapy.

New research suggests Alzheimer's drugs may improve cognition by increasing Aβ42 levels rather than just reducing plaques, challenging the amyloid cascade hypothesis and pointing to new therapeutic strategies focused on restoring soluble Aβ42 to maintain brain health.

The MIND diet slows cognitive decline in older adults, with Black participants requiring stricter adherence for benefits. Racial and gender differences suggest broader social, lifestyle, and biological factors influence the diet's effectiveness.

Researchers observed that amyloid-beta and tau proteins are associated with a transition from hyperactivity to slower brain activity, which aligns with declines in attention and memory, suggesting potential early indicators of Alzheimer’s disease progression.

APOE4 carriers had higher blood-brain barrier permeability, even without cognitive decline or amyloid beta buildup, suggesting early vascular changes that may be linked to Alzheimer’s risk and neurodegeneration.

A study found untreated hypertension increases Alzheimer's risk by 36% and non-Alzheimer's dementia risk by 69%. Treating hypertension lowers these risks, highlighting the importance of antihypertensive medication.

Researchers discovered that Alzheimer’s disease progresses in two phases: a slow, early phase with silent damage to specific brain cells, followed by a faster, symptomatic phase. These insights could lead to earlier detection and targeted treatments.

Researchers have discovered that non-neuronal brain cells, oligodendrocytes, produce about 30% of amyloid plaques in Alzheimer’s disease. This challenges the neuron-focused understanding of plaque formation and could lead to new therapeutic strategies targeting oligodendrocytes to slow disease progression.